The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
@HereforHemo I think you are wrong. It is my understanding that following IND submission there is a 30 day period in which the FDA can apply a clinical hold, failing this on day 31 Hemogenyx can commence clinical trials, they can ship and prepare for trials during that 30 day window. Fast track/breakaway apply to the NDA process which affects how quickly the FDA will examine and the level of clinical evidence required before a drug is approved.
Russian and Ukrainian negotiators have ended the first direct talks in more than two weeks in Istanbul, with Moscow saying it was ready to “fundamentally cut back” military activity near the Ukrainian capital of Kyiv and the northern city of Chernihiv.
Deputy Defence Minister Alexander Fomin said the move was meant “to increase trust” in talks aimed at ending the fighting, as negotiators met face-to-face on Tuesday after several rounds of failed talks.
@Hemotruth if the Share Price is not going to move with the news we have had recently then I too would hope for a hostile takeover. We are a few weeks from the 52 week high dropping to 3.1p so £30 million less any discount by buying the initial 30% between 1-1.5p.
Is cash on hand + patents worth more than £25-£30 million?
We would have to vote to accept or reject any offer as Dr Sandler and his wife have only a minority stake, I would probably vote in favour of a takeover at this point like yourself.
No question the long term potential for Hemogenyx is fantastic, but I would rather a 100% risk free return in the short term vs a potential long term return that comes with the risk of dilution or failure at trials.
@JustHereForHemo That is very useful, thanks, makes more sense than the RNS assuming you are correct, however it does say "modular synthetic receptors that can be reconfigured" so perhaps your explanation is a little over simplified? @MrIndia many of those printed as sells are buys, but I agree with you 11% on what looks like a ground breaking update is just impossible to understand. A tiny company like Hemogenyx with a potential cure for any virus?
And another undisclosed partner? My criticism would be that if CBR is as good as it appears, if its groundbreaking with the potential to transform viral treatments then why is this such a low brow reveal? Dr Sandler has delivered in the lab and hoped the science would do the talking. At a bare minimum I would expect to see an interview with him explaining CBR in clear English, there should be papers published, articles in publications, update on company website which has no mention of CBR. I am critical of the PR but that can be fixed, the science is the foundation and that looks good.
@Human_sundial the simple truth is we have no idea what will change between now and May when the meeting which they have told us is very unlikely to be required is scheduled too. We await updates on CBR, CDX, Hu-PHEC and we await an IND application for CAR-T which could come at any time between now and end of the year.
@tuan6 you are correct, they have IP which is valuable, however when you look at the current mCap it is valued at nothing, there is something wrong there. Potential future revenues and value for IP should be factored in to companies otherwise every single pre-clinical pharma would have an mCap of 0 which is clearly not the case.
@MrIndia - Dont even think of trying to play the "I am being bullied card."
Nobody here goes out of their way to attack you however its always you who wants to drag the board down. When the SP is red you are posting about how can anyone be selling and your usual drivel. Now the SP is blue and you have dragged this board into an argument about YOU.
"It is JUST blue by a few percent so let's not get carried away." - Unless its red then it does not matter what percent you will start complaining.
"Its a real shame since once upon a time we all spoke about the upcoming news" - Now even though they are moving closer and closer to IND as per official RNS updates we spend all our time talking about MrIndia.
@MrIndia - We had the broken record about how nobody trusted Dr Sandler and how the world was ending and everyone was selling this morning when the SP was red.
Now the SP is blue is it your intentions to now say how everyone trusts Dr Sandler and the world is saved and everyone is buying? Or do you only wish to comment when the SP is red?
Simple fact is there is a war ongoing, the market crashed, we saw 2 consecutive -10% red days at Hemogenyx and that is unsustainable, the Fear Factor certainly plays a part but the weak hands can only sell once. We are all still alive so I suspect we have not seen the start of a nuclear war yet and as this becomes something of a "new normal" investors will return to the markets. Have you considered a hobby? The amount of time you appear to spend daily watching this stock and posting on these boards cannot be healthy.
@Hemotruth I said "almost", in addition to the orgenesis repayment of 1.5m there was a 250k payment to Eli Lilly.
On 30 June 2021 total assets was 11.1m and looking at their figures they have a burn of ~ 2mil per year, the 2,650,762 additional loss reported last year was "Finance Costs" IE one off losses incurred with Placings/CLN. Given they have yet to move into the new lab (That we know about) then its unlikely they have spent much more than 2mil in the 8 months since last reporting which would be in the 7.5m ballpark, not far from the ~10m mCap this morning.
@cs123, you may have missed it but there has been a war ongoing in Ukraine... Nothing linked to developments either with Hemogenyx or likely to impact the company in the longer scale. Spooked market, margin calls and lack of confidence in shares as a whole. However looking at the bigger picture if hostilities end there will be a sharp and sudden bounce across the market. Russia has moved the bar lower no doubt in response to the economic impact of crippling sanctions and are now demanding:
"Kremlin spokesman Dmitry Peskov says Ukraine must recognise Crimea as Russian, and Donetsk and Luhansk as independent states.
In addition to this, Peskov says Ukraine must amend its constitution and reject claims to enter any bloc (like Nato, for example)."
This is significantly less than their original aims and some of these demands such as giving up claims to Crimea are likely to be acceptable if it means an end to the war. With an mCap of 10mil Hemogenyx are sitting at almost cash levels with expected news on IND application imminently and updates pending on CBR and CDX. It feels like we have already experienced the worst of any drop, the fear factor is receding and a diplomatic outcome is the more likely outcome.
@Mickyc333 - I can understand your confusion, allow me to translate:
Ssccss - "I've sold out. I'm not sticking around to watch this go under 1p. Vlad has destroyed Hemo. Good luck all."
Translation - I've sold out. I like to trade this stock though so I'm sticking around hoping this will go under 1p. Going to blame Vlad for the war in Ukraine. Good luck to me, hopefully I can buy in lower.
Ssccss - "Very short memories and lots of rose-tinted glasses. How much pain will you take... good luck."
Translation - Gee I had hoped the SP would have went towards 1p instead of rising a bit after I sold. How much would it cost me to buy back if there was a bounce... good luck to me I am going to need it.
Was just in the process of placing an order for Poly, however within the last few minutes the brokers have suspended trading, you can sell but you cannot buy, I suspect some sort of additional sanction or risk mitigation policy has come into play. Disappointing as was happy to take a small position at least until post ex-dividend.
@didso people who post a comment like this usually regret it, if there is an update or bounce in the next few days its likely people will use this to troll you. I cannot be critical of your decision to sell, its a depressing time and the conflict in Ukraine makes investing anywhere fraught with risk. Leaving however as you have chosen to do with an attack and the proverbial knife in the back is very unsportsmanlike.
I have not scaled back here because apart from the doom and gloom on this forum my understanding based on official statements and updates from Hemogneyx themselves is:
CAR-T is progressing well towards clinical trials which is funded
An FDA Pre-IND meeting is scheduled for May but very unlikely to get that far as communications are ongoing with FDA as we speak
CBR update expected soon
CDX progressing well with new partnership announced recently
Bullish posts from Hemogenyx that things are progressing.
I chose not to listen to the trolls who will only point out the Share Price which has fallen,I am fully aware of this, I have eyes, this does not justify further heavy falls.
Setting Hemogenyx aside for a moment, talks are due to commence soon between Ukraine and Russia, a ceasefire is probably unlikely but possible. Any move towards peace and de-escalation would likely ripple across the markets and would likely bounce Hemo even without volume.
@Pingu777 I would not waste your time getting into it with @one2one, I have noticed that they randomly pop up, post a quick link and disappear. The reason for the post appears to be usually either cross ramping or to try and sow doubt or make it look like some competition has popped up.
Good morning @dhub I do wonder where you get your figures from and why you obsess so much, clearly you are using a poor broker who is approaching a very limited selection of market makers. I can get a quote to sell or buy millions of shares right now which tells me absolutely nothing.
We are into march tomorrow, I believe a few posters have commented that the new Lab move is due in March and that has to happen before any IND application? If there are no delays it could be a very good few weeks ahead with plenty of opportunities to keep investors updated on progress.